

Focus on Peripheral Biomarkers of Mental Disorders

Francesco Bartoli ^{1,*} and Giuseppe Carrà ^{1,2}

¹ Department of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, MB, Italy; giuseppe.carra@unimib.it

² Division of Psychiatry, University College London, 6th Floor, Maple House, 149 Tottenham Court Road, London W1T7NF, UK

* Correspondence: francesco.bartoli@unimib.it

Personalized approaches in psychiatry, albeit being extensively explored in the literature since the early 2010s [1–4], are far from being routinely used in clinical practice. Indeed, compared with other clinical fields, which have already filled the translational gap, psychiatry has not yet benefited from the advanced methodologies needed for precision medicine [1]. Although research resources have been extensively allocated to the aims of this approach [5,6], the biological underpinnings of mental disorders remain unknown [7]. The identification of valid biomarkers would represent an important step towards precision psychiatry with the goal of supporting personalized approaches for prevention, diagnosis, and treatment of mental disorders in clinical practice [8]. Consistently, in the last few years, research has paid attention to this topic, generating several systematic syntheses on biomarkers belonging to inflammatory, immune, and oxidative stress pathways [8–17]. Nonetheless, evidence emerging from this large body of scientific literature around different mental disorders is still not convincing and requires additional studies [8].

Following this perspective, the goal of this special issue entitled “*Peripheral Biomarkers of Mental Disorders and Related Clinical Features*” was to provide additional insight into this topic, including 10 relevant studies from key experts in the field [18–27], with the majority of them investigating the cutting-edge topics of affective disorders.

In our opinion paper [18], co-authored with the pioneer of purinergic signaling, Professor Geoffrey Burnstock [28,29], we explored the neurobiological background of the hypothesized link between the purinergic pathway and mood disorders. The potential role of the adenosine and ATP-mediated signaling at P1 and P2 receptors in depression, the antidepressive effects of non-selective adenosine antagonists, and the promising role of peripheral adenosine metabolites as biomarkers of depression were all extensively described.

Fusar-Poli et al. [21], testing the role of inflammation in different phases of bipolar disorder, investigated whether neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), and monocyte-to-lymphocyte (MLR) ratios might represent potential biomarkers of mood episodes in 294 individuals with bipolar disorder. NLR, PLR, and MLR in study participants with hypo/manic episodes were significantly higher than in those with a depressive episode, and PLR was estimated as an independent predictor of mania. In another study, exploring the role of parathyroid hormone (PTH), vitamin D, and serum calcium in 199 individuals with bipolar disorder, Steardo et al. [25] found that PTH levels correlated with different clinical characteristics, such as psychotic features, suicidal behaviors, and the number of mood relapses. The authors suggested that calcium homeostasis could play a role in bipolar disorder and that PTH levels might be correlated with the clinical severity of the disorder. Moreover, Reginia et al. [23], comparing 30 individuals suffering from bipolar disorder and 30 healthy controls, hypothesized abnormalities in regenerative processes in bipolar disorder, even though no differences

Citation: Bartoli, F.; Carrà, G. Focus on Peripheral Biomarkers of Mental Disorders. *Brain Sci.* **2022**, *12*, 756. <https://doi.org/10.3390/brainsci12060756>

Received: 15 May 2022

Accepted: 2 June 2022

Published: 8 June 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

in stem-cell levels between groups were estimated. In addition, in their opinion article, Wollenhaupt-Aguiar et al. [25] overviewed putative molecular pathways and biomarkers of neuroprogression possibly affecting clinical outcomes, cognition, and functioning of bipolar disorder; they suggested that multiple factors play a role in bipolar disorder, factors such as inflammation, oxidative stress, impaired calcium signaling, mitochondrial dysfunctions, and impaired neuroplasticity.

Berardelli et al. [19], in a systematic review of data from 36 studies, suggested an involvement of the hypothalamic–pituitary–adrenal (HPA) axis on the pathophysiological processes associated with suicidal behaviors, discussing the potential implications in terms of relevant treatments.

Vismara et al. [26] also ran a review, this on the available evidence about the peripheral biomarkers of anxiety disorders, showing mixed findings for the cerebrospinal fluid and blood biomarkers related to neurotransmitters, neuropeptides, the HPA axis, neurotrophic factors, and the inflammatory system.

Finally, Maes et al. [22], using data from 80 participants with schizophrenia and 40 healthy controls, and integrating clinical information—such as specific symptoms of psychosis, self-reported quality of life, memory, and executive functions—with different inflammatory, immunological, and oxidative stress biomarkers, hypothesized new diagnostic subclasses of schizophrenia.

The content of this special issue may represent a preliminary, though still meaningful, contribution to the scientific evidence on biomarkers of mental disorders and related behaviors. Main efforts of research in biological psychiatry are moving towards novel approaches and new advancements for diagnosis and treatment of mental disorders. Relevant progress in the identification of peripheral biomarkers may improve the effectiveness of mental health care and address some of the unmet needs in the clinical management of severe mental disorders.

This special issue is also our tribute to Professor Geoffrey Burnstock, who died a few months after the publication of our opinion article at the age of 91 [28,29]. His contribution to our paper was generous and enthusiastic. Throughout the world there are many who owe him a similar debt of gratitude.

Author Contributions: Writing—original draft preparation, F.B.; writing—review and editing, G.C. F.B. and G.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: We thank all the authors of studies included in our special issue.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Fernandes, B.S.; Williams, L.M.; Steiner, J.; Leboyer, M.; Carvalho, A.F.; Berk, M. The new field of ‘precision psychiatry’. *BMC Med.* **2017**, *15*, 80.
2. Ozomaro, U.; Wahlestedt, C.; Nemeroff, C.B. Personalized medicine in psychiatry: Problems and promises. *BMC Med.* **2013**, *11*, 132.
3. Passos, I.C.; Ballester, P.; Rabelo-da-Ponte, F.D.; Kapczinski, F. Precision Psychiatry: The Future Is Now. *Can. J. Psychiatry* **2022**, *67*, 21–25.
4. Roffman, J.L. Biomarkers and personalized psychiatry. *Harv. Rev. Psychiatry* **2011**, *19*, 99–101.
5. Cuthbert, B.N.; Insel, T.R. Toward the future of psychiatric diagnosis: The seven pillars of RDoC. *BMC Med.* **2013**, *11*, 126.
6. Insel, T.R. The NIMH Research Domain Criteria (RDoC) Project: Precision medicine for psychiatry. *Am. J. Psychiatry* **2014**, *171*, 395–397.
7. Kelly, R.E., Jr.; Ahmed, A.O.; Hoptman, M.J.; Alix, A.F.; Alexopoulos, G.S. The Quest for Psychiatric Advancement through Theory, beyond Serendipity. *Brain Sci.* **2021**, *12*, 72.
8. Carvalho, A.F.; Solmi, M.; Sanches, M.; Machado, M.O.; Stubbs, B.; Ajnakina, O.; Sherman, C.; Sun, Y.R.; Liu, C.S.; Brunoni, A.R.; et al. Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. *Transl. Psychiatry* **2020**, *10*, 152.
9. Almulla, A.F.; Vasupanrajit, A.; Tunvirachaisakul, C.; Al-Hakeim, H.K.; Solmi, M.; Verkerk, R.; Maes, M. The tryptophan catabolite or kynurenine pathway in schizophrenia: Meta-analysis reveals dissociations between central, serum, and plasma compartments. *Mol. Psychiatry* **2022**. <https://doi.org/10.1038/s41380-022-01552-4>.

10. Bartoli, F.; Misiak, B.; Callovini, T.; Cavaleri, D.; Cioni, R.M.; Crocamo, C.; Savitz, J.B.; Carrà, G. The kynurenine pathway in bipolar disorder: A meta-analysis on the peripheral blood levels of tryptophan and related metabolites. *Mol. Psychiatry* **2021**, *26*, 3419–3429.
11. Bartoli, F.; Misiak, B.; Crocamo, C.; Carrà, G. Glial and neuronal markers in bipolar disorder: A meta-analysis testing S100B and NSE peripheral blood levels. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **2020**, *101*, 109922.
12. Belbasis, L.; Köhler, C.A.; Stefanis, N.; Stubbs, B.; van Os, J.; Vieta, E.; Seeman, M.V.; Arango, C.; Carvalho, A.F.; Evangelou, E. Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: An umbrella review of meta-analyses. *Acta Psychiatr. Scand.* **2018**, *137*, 88–97.
13. Dunleavy, C.; Elsworth, R.J.; Upthegrove, R.; Wood, S.J.; Aldred, S. Inflammation in first-episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis. *Acta Psychiatr. Scand.* **2022**. <https://doi.org/10.1111/acps.13416>.
14. Fraguas, D.; Díaz-Caneja, C.M.; Ayora, M.; Hernández-Álvarez, F.; Rodríguez-Quiroga, A.; Recio, S.; Leza, J.C.; Arango, C. Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis. *Schizophr. Bull.* **2019**, *45*, 742–751.
15. Misiak, B.; Bartoli, F.; Carrà, G.; Małecka, M.; Samochowiec, J.; Jarosz, K.; Banik, A.; Stańczykiewicz, B. Chemokine alterations in bipolar disorder: A systematic review and meta-analysis. *Brain Behav. Immun.* **2020**, *88*, 870–877.
16. Misiak, B.; Bartoli, F.; Carrà, G.; Stańczykiewicz, B.; Gładka, A.; Frydecka, D.; Samochowiec, J.; Jarosz, K.; Hadryś, T.; Miller, B.J. Immune-inflammatory markers and psychosis risk: A systematic review and meta-analysis. *Psychoneuroendocrinology* **2021**, *127*, 105200.
17. Pinto, J.V.; Moulin, T.C.; Amaral, O.B. On the transdiagnostic nature of peripheral biomarkers in major psychiatric disorders: A systematic review. *Neurosci. Biobehav. Rev.* **2017**, *83*, 97–108.
18. Bartoli, F.; Burnstock, G.; Crocamo, C.; Carrà, G. Purinergic Signaling and Related Biomarkers in Depression. *Brain Sci.* **2020**, *10*, 160.
19. Berardelli, I.; Serafini, G.; Cortese, N.; Fiaschè, F.; O'Connor, R.C.; Pompili, M. The Involvement of Hypothalamus-Pituitary-Adrenal (HPA) Axis in Suicide Risk. *Brain Sci.* **2020**, *10*, 653.
20. Fabrazzo, M.; Zampino, R.; Vitrone, M.; Sampogna, G.; Del Gaudio, L.; Nunziata, D.; Agnese, S.; Santagata, A.; Durante-Mangoni, E.; Fiorillo, A. Effects of Direct-Acting Antiviral Agents on the Mental Health of Patients with Chronic Hepatitis C: A Prospective Observational Study. *Brain Sci.* **2020**, *10*, 483.
21. Fusar-Poli, L.; Natale, A.; Amerio, A.; Cimpoesu, P.; Grimaldi Filioli, P.; Aguglia, E.; Amore, M.; Serafini, G.; Aguglia, A. Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte and Monocyte-to-Lymphocyte Ratio in Bipolar Disorder. *Brain Sci.* **2021**, *11*, 58.
22. Maes, M.; Vojdani, A.; Galecki, P.; Kanchanatawan, B. How to Construct a Bottom-Up Nomothetic Network Model and Disclose Novel Nosological Classes by Integrating Risk Resilience and Adverse Outcome Pathways with the Phenome of Schizophrenia. *Brain Sci.* **2020**, *10*, 645.
23. Reginia, A.; Samochowiec, J.; Jabłoński, M.; Ferensztajn-Rochowiak, E.; Rybakowski, J.K.; Telesiński, A.; Tarnowski, M.; Misiak, B.; Ratajczak, M.Z.; Kucharska-Mazur, J. Markers of Regenerative Processes in Patients with Bipolar Disorder: A Case-control Study. *Brain Sci.* **2020**, *10*, 408.
24. Silva Ribeiro, J.; Pereira, D.; Salagre, E.; Coroa, M.; Santos Oliveira, P.; Santos, V.; Madeira, N.; Grande, I.; Vieta, E. Risk Calculators in Bipolar Disorder: A Systematic Review. *Brain Sci.* **2020**, *10*, 525.
25. Steardo, L., Jr.; Luciano, M.; Sampogna, G.; Carbone, E.A.; Caivano, V.; Di Cerbo, A.; Giallonardo, V.; Palummo, C.; Vece, A.; Del Vecchio, V. Clinical Severity and Calcium Metabolism in Patients with Bipolar Disorder. *Brain Sci.* **2020**, *10*, 417.
26. Vismara, M.; Girone, N.; Ciriogliaro, G.; Fasciana, F.; Vanzetto, S.; Ferrara, L.; Priori, A.; D'Addario, C.; Viganò, C.; Dell'Oso, B. Peripheral Biomarkers in DSM-5 Anxiety Disorders: An Updated Overview. *Brain Sci.* **2020**, *10*, 564.
27. Wollenhaupt-Aguilar, B.; Kapczinski, F.; Pfaffenseller, B. Biological Pathways Associated with Neuroprogression in Bipolar Disorder. *Brain Sci.* **2021**, *11*, 228.
28. Abbracchio, M.P.; Jacobson, K.A.; Müller, C.E.; Zimmermann, H. Professor Dr. Geoffrey Burnstock (1929–2020). *Purinergic Signal.* **2020**, *16*, 137–149.
29. Abbracchio, M.P. The history of the Purine Club: A tribute to Prof. Geoffrey Burnstock. *Purinergic Signal.* **2021**, *17*, 127–134.